Steven E. North, Esq.
Prostate cancer is the second-most common cancer among men: More than 70 men die from it daily in the U.S., and hundreds of thousands more undergo testing and treatment for low-risk prostate cancer that is not likely to harm them. The changing nature of data revealed by research about the disease makes it increasingly perplexing to determine the best course for diagnosis and management.
It is essential that patients are fully informed of their options so that they, rather than – or in conjunction with – their physicians play the most important role in determining whether to move forward with biopsy and repeat biopsy, robotic surgery, radiation (external beam or brachytherapy), or watchful surveillance.
The fact is that in a low-risk-patient the side effects of treatment can be more harmful than the disease itself, namely severe bowel, bladder and erectile problems. Patients may also be subject to severe infection from surgery or a biopsy, incomplete robotic removal of the cancer, and even death.
A high majority of prostate cancers, however, grow so slowly, it is likely that the patient will die of some other cause. Some poorly advised patients opt for radical surgery or other aggressive means because they want the cancer out. They do not understand that careful monitoring generally allows for timely intervention should a lesion become more aggressive.
The critical determining factor in choosing a protocol is the nature of the cancer itself: Is it aggressive, slow growing, metastasized? A patient’s age or life expectancy should also drive the treatment or management decision. A senior citizen can outlive the cancer, whereas a younger man may need more aggressive management.
Fortunately, new tests can more clearly indicate the aggressiveness of a cancer. As more new tests emerge, it is expected that more men will learn that they have slow-growing cancers that require nothing more than periodic surveillance. The real test will be whether a patient is confident enough in this assessment to forego a treatment that can eradicate his cancer.
The prostate cancer cases that end up in medical malpractice litigation are often those where the PSA test result is overlooked by the physician or the acceleration rate of change in the results is not appreciated.
Reference: The Wall Street Journal, May 10, 2015 page D1
Back to Medical Malpractice Attorney NYC
By NYC Attorney of Your Medical Malpractice Claim
Phone (212) 861-5000
By Email : Click here
We thank you for your Negotiating tenacity... The award was so much more than either Denise or I anticipated... Read more.
Sally and Denise
Specialist in Cases Involving Significant Damages • Listed in Best Lawyers • Listed in Who’s Who • Commentator, Court T.V., Eyewitness News, Talk News T.V. • Contributing Author, New York Law Journal Author of Numerous Publications • Faculty Chairman, Continuing Legal Education Programs • Trial Lawyer and Bar Association Committees
1988, New York and U.S. District Court, Northern, Southern, Eastern and Western Districts of New York. Union College, Schenectady, B.A., magna cum laude, 1984 Phi Beta Kappa; University of Chicago Law School, J.D., 1987
Receive a complimentary consultation from one of our experienced attorneys.